Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis [3]

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3459-3460

  Weiler, Stefan ^a   Zoller, Heinz ^a   Graziadei, Ivo ^a   Vogel, Wolfgang ^a   Bellmann Weiler, Rosa ^a   Joannidis, Michael ^a   Bellmann, Romuald ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; VORICONAZOLE;

ADULT; ANTIFUNGAL ACTIVITY; ASPERGILLUS; BLURRED VISION; CANDIDA; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; FUSARIUM; GLASGOW COMA SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; MALE; PRIORITY JOURNAL; SCEDOSPORIUM;

ANTIFUNGAL AGENTS; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 35948940028     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00791-07     Document Type: Letter

References (11)

1. Den Hollander, J. G., C. van Arkel, B. J. Rijnders, P. J. Lugtenburg, S. de Marie, and M. D. Levin. 2006. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J. Antimicrob. Chemother. 57:1248-1250.
2. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
3. Khoschsorur, G., F. Fruehwirth, and S. Zelzer. 2005. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob. Agents Chemother. 49:3569-3571.
4. Kullberg, B. J., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. Church, J. M. Brown, H. T. Schlamm, I. T. Oborska, F. Hilton, and M. R. Hodges. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442.
5. Pascual, A. A., S. Bolay, and O. Marchetti. 2006. Monitoring of voriconazole (VRC) blood levels for prevention of serious neurological adverse events (SNAE). Int. J. Infect. Dis. 10:S67.
6. Potoski, B. A., and J. Brown. 2002. The safety of voriconazole. Clin. Infect. Dis. 35:1273-1275.
7. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
8. Roffey, S. J., S. Cole, P. Comby, D. Gibson, S. G. Jezequel, A. N. Nedderman, D. A. Smith, D. K. Walker, and N. Wood. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741.
9. Smith, J., N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
10. Tan, K., N. Brayshaw, K. Tomaszweski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
11. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinhardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, E. Anaissie, and J. Lee. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.